Keyup Listener: window.performance.mark

keyup listener: Thomas Cannell, president and chief executive officer of Sesen Bio, according to The Independent. I'm delighted to have Mark, Erin, Monica and Omar in these key leadership positions to help accelerate the Company's progress towards key milestones. Search first keyup' ; ; listener ; ;No matching results for ''Tip Try a valid symbol or a specific company name for relevant results Cancel Sign in Mailif window.performance window.performance.mark && && Finance Techif window.performance window.performance.mark && && U.S. Markets open in 4 hrs 23 minsS&P window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && Bio Strengthens Leadership Teamif window.performance window.performance.mark && && Wire August 5, 2019if window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && window.performance window.performance.mark && && Mass.-- BUSINESS WIRE --Company Appoints Seasoned Biotech Leaders to Oversee Legal, Corporate Strategy, Financial Planning, and Business Development and Alliance Management Sesen Bio Nasdaq SESN a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced industry leaders to several key roles Mark R. Sullivan to General Counsel and Corporate Secretary Erin Clark to Vice President, Corporate Strategy and Investor Relations Monica Forbes to Vice President, Finance Omar Rifi to Vice President, Business Development and Alliance Management The financing in the second quarter has enabled us to build additional capabilities as we work diligently to prepare for the anticipated initiation of our BLA submission for Vicinium in the fourth quarter, said Dr. All four of these individuals not only bring impressive track records and diverse skill sets to Sesen, but also believe very strongly in our mission to save and improve the lives of patients with cancer. Mr. Mark R. Sullivan has more than 20 years of legal experience in the life sciences and healthcare industries. (news.financializer.com). As reported in the news.